UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Haematologica (Roma), 2016-07, Vol.101 (7), p.e295-e298

2016

Volltextzugriff (PDF)

The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars

The oncologist (Dayton, Ohio), 2018-03, Vol.23 (3), p.288-296

2018

Volltextzugriff (PDF)

The Emergency Medical Responder: Training and Succeeding As an EMT/EMR

1st ed. 2021., 2021

Volltextzugriff (PDF)

Rituximab biosimilars in hematologic malignancies: the need for a real-world approach

Future oncology (London, England), 2020-09, Vol.16 (26), p.2017-2027

2020

Volltextzugriff (PDF)

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-07, Vol.35 (4), p.459-468

2021

Volltextzugriff (PDF)

The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2675-TPS2675

2022

Volltextzugriff (PDF)

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma

Clinical lymphoma, myeloma and leukemia, 2018-08, Vol.18 (8), p.508-518.e14

2018

Volltextzugriff (PDF)

Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14508-e14508

2023

Volltextzugriff (PDF)

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2533-2533

2023

Volltextzugriff (PDF)

Endothelin Mediation of Insulin and Glucose-Induced Changes in Vascular Contractility

Hypertension (Dallas, Tex. 1979), 1997-10, Vol.30 (4), p.825-829

1997

Volltextzugriff (PDF)

Coronary and femoral arterial contraction with high glucose, insulin, and glucose-insulin-potassium solution: effects of hypoxia

Heart and vessels, 2002-01, Vol.16 (2), p.57-63

2002

Volltextzugriff (PDF)

Factors Infuencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-07, Vol.35 (4), p.459-468

2021

Volltextzugriff (PDF)

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors

Clinical cancer research, 2015-02, Vol.21 (4), p.693-700

2015

Volltextzugriff (PDF)

Factors influencing infusion-related reactions following dosing of reference rituximab (RTX) and PF-05280586, a RTX biosimilar

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20049-e20049

2020

Volltextzugriff (PDF)

Breast cancer vaccines: maximizing peptide-based vaccines by regulatory T cell depletion and toll-like receptor 9 activation

BMC cancer, 2007-02, Vol.7 (S1), p.A2-A2, Article A2

2007

Volltextzugriff (PDF)

Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

Cancer research (Chicago, Ill.), 2007-02, Vol.67 (3), p.1326-1334

2007

Volltextzugriff (PDF)

Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo

The Journal of immunology (1950), 2008-09, Vol.181 (5), p.3137-3147

2008

Volltextzugriff (PDF)

AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study

JCO global oncology, 2023-08, Vol.9 (Supplement_1), p.26-26

2023

Volltextzugriff (PDF)

746 AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the phase 1 dose-escalation study

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A779-A779

2022

Volltextzugriff (PDF)

Tratamiento del penfigoide de membranas mucosas con ácido hialurónico en gel al 0,2%. Reporte de caso

Revista Estomatológica Herediana, 2022-12, Vol.32 (4), p.428-434

2022

Volltextzugriff (PDF)

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Blood, 2013-11, Vol.122 (21), p.1630-1630

2013

Volltextzugriff (PDF)

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton's Tyrosine Kinase (Btk) Inhibitor CC-292

Blood, 2013-11, Vol.122 (21), p.4169-4169

2013

Volltextzugriff (PDF)

Effects of polarizing solution on glucose uptake of rat oxygenated or hypoxic ventricular myocytes

Clinical and experimental pharmacology & physiology, 2003-01, Vol.30 (1-2), p.64-71

2003

Volltextzugriff (PDF)

IL-10 secretion from BALB-neuT mice cells after stimulation with murine breast tumor cell lines (88.28)

The Journal of immunology (1950), 2007-04, Vol.178 (1_Supplement), p.S144-S144

2007

Volltextzugriff (PDF)

17 beta-estradiol modulates effects of insulin-induced changes in vascular contractility

Archivos de cardiología de México, 2003-10, Vol.73 (4), p.253-260

2003

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(146)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars

The Emergency Medical Responder: Training and Succeeding As an EMT/EMR

Rituximab biosimilars in hematologic malignancies: the need for a real-world approach

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma

Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort

Endothelin Mediation of Insulin and Glucose-Induced Changes in Vascular Contractility

Coronary and femoral arterial contraction with high glucose, insulin, and glucose-insulin-potassium solution: effects of hypoxia

Factors Infuencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors

Factors influencing infusion-related reactions following dosing of reference rituximab (RTX) and PF-05280586, a RTX biosimilar

Breast cancer vaccines: maximizing peptide-based vaccines by regulatory T cell depletion and toll-like receptor 9 activation

Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo

AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study

746 AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the phase 1 dose-escalation study

Tratamiento del penfigoide de membranas mucosas con ácido hialurónico en gel al 0,2%. Reporte de caso

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton's Tyrosine Kinase (Btk) Inhibitor CC-292

Effects of polarizing solution on glucose uptake of rat oxygenated or hypoxic ventricular myocytes

IL-10 secretion from BALB-neuT mice cells after stimulation with murine breast tumor cell lines (88.28)

17 beta-estradiol modulates effects of insulin-induced changes in vascular contractility

Suchergebnisse filtern